PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology

Prospective real-world evidence for the use of immune-checkpoint inhibitors and BRAF-targeted therapy in advanced melanoma from a large Canadian cohort.

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJohn LenehanDED. Scott ErnstLYLeah Young

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lenehan et al. (2024) studied this question.

synapsesocial.com/papers/68e673edb6db6435875fe135https://doi.org/10.1200/jco.2024.42.16_suppl.e21533
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA2026
  2. 2Sequential therapy in BRAF-mutant melanoma: Comparison of combination immunotherapy anti-CTLA4 and anti–PD-1 versus anti–PD-1 monotherapy after targeted treatment failure.2026
  3. 3Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors.2024
  4. 4The outcome in patients with <scp>BRAF</scp>‐mutated metastatic melanoma treated with <scp>anti‐programmed</scp> death receptor‐1 monotherapy or targeted therapy in the real‐world setting2024 · 4 citations
  5. 5Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.2024 · 1 citations